Rare Genetic Syndromes as a Window into the Genetic Architecture of Mental Disorders (Collaborative U01 Clinical Trial Not Allowed) | RFA MH 19 201

Opportunity Information: Apply for RFA MH 19 201

The funding opportunity "Rare Genetic Syndromes as a Window into the Genetic Architecture of Mental Disorders (Collaborative U01 Clinical Trial Not Allowed)" is a National Institutes of Health (NIH) cooperative agreement initiative (U01 mechanism) designed to use rare genetic syndromes as powerful models for understanding the genetic basis of mental and neuropsychiatric disorders. The central idea is that rare, clearly defined genetic conditions can act like a magnifying glass for studying how genetic variation contributes to psychiatric and neurodevelopmental features, and how those features overlap with more common, "idiopathic" mental disorders that do not have a single known cause.

Scientifically, the program focuses on explaining why people who share the same rare genetic diagnosis can still show very different clinical outcomes. It specifically targets two long-standing challenges in human genetics: variable expressivity (the same genetic syndrome leading to different types or severities of symptoms across individuals) and incomplete penetrance (some individuals carrying a high-risk genetic variant but showing few or no symptoms). Applicants are expected to use genome-wide data to move beyond single-gene explanations and instead examine the broader genetic architecture that shapes neuropsychiatric traits. This includes assessing how multiple forms of genetic variation, potentially including common variants and additional rare variants elsewhere in the genome, influence whether and how psychiatric phenotypes emerge in a given syndrome.

A major emphasis is placed on rigorous, high-quality phenotyping across rare genetic disorders and across developmental time. The FOA encourages investigators to improve the depth, consistency, and comparability of clinical data by developing or applying standardized phenotyping approaches that can be used across multiple syndromes and at different ages. In practice, this means creating or refining assessment pipelines that allow researchers to harmonize measures of cognition, behavior, psychiatric symptoms, and related neurodevelopmental outcomes so that findings can be compared across disorders and across studies without the usual problems caused by mismatched instruments or inconsistent clinical definitions.

The initiative is structured to build a coordinated research network that supports data sharing, harmonization, and joint progress across funded projects. Even when projects are conducted at a single site (or are not dependent on multiple collaborating sites), they are still expected to operate as part of a broader framework that accelerates genotype-to-phenotype mapping across rare genetic disorders. A key deliverable is the creation of a broadly useful research resource, including biospecimens as well as well-curated phenotypic and genetic datasets that can be shared with the wider scientific community. In other words, the program is not just funding individual studies; it is also investing in infrastructure and shared assets that can keep generating value after the initial projects are completed.

Administratively, this opportunity uses the cooperative agreement model, which generally means there is substantial NIH involvement compared to a standard research grant. All awards made under this FOA and its companion announcement are governed by the Mental Health Rare Genetic Disease Network (MHRGDN), which serves as the organizing structure for network coordination, common standards, and shared goals. The FOA clarifies an important submission rule: it is intended for applications that are not collaborative between sites. Projects that require two or more collaborating sites to complete the research are directed to apply as a linked set of collaborative U01 applications under the companion collaborative U01 FOA. The "Clinical Trial Not Allowed" designation indicates the work should not involve clinical trials as defined by NIH policy, keeping the focus on genetic and phenotypic characterization, data generation, and analytic approaches rather than testing interventions.

In terms of eligibility and participation, the program is broadly open to a wide range of organizations, reflecting NIH's typical inclusivity for biomedical research funding. Eligible applicants include various levels of government (state, county, city/township, special districts), school districts, public and private institutions of higher education, nonprofit organizations (with or without 501(c)(3) status), for-profit organizations (other than small businesses), small businesses, and tribal entities. The announcement also explicitly highlights additional eligible applicant types such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, tribally controlled colleges and universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), faith-based or community-based organizations, U.S. territories or possessions, and non-U.S. (foreign) organizations and regional organizations. This broad eligibility aligns with the program's reliance on existing cohorts, specialized clinics, and established networks that may be distributed across different institutional settings and geographies.

Key identifying details from the source include the funding opportunity number RFA-MH-19-201, the NIH as the issuing agency, and classification within Health and related services (CFDA numbers 93.242 and 93.865). The original closing date listed is 2018-08-09, with the creation date 2018-06-07. While the notice text emphasizes coordinated network behavior and resource generation, it also signals that applicants are expected to leverage existing cohorts and infrastructure whenever possible, suggesting that readiness, access to well-characterized participants, and the ability to produce harmonized high-quality phenotype and genome-wide data are central to competitiveness under this program.

• The National Institutes of Health in the health, income security and social services sector is offering a public funding opportunity titled "Rare Genetic Syndromes as a Window into the Genetic Architecture of Mental Disorders (Collaborative U01 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242, 93.865.
• This funding opportunity was created on 2018-06-07.
• Applicants must submit their applications by 2018-08-09. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA MH 19 201

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: